Ardelyx, Inc.

Raab continued, In addition to driving significant revenue growth, we carefully managed investments and closed on an option to draw additional debt at a reasonable cost.

SEC original ↗Ardelyx, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

The amendment also provides the Company with the option to draw an additional $100.0 million of debt, consisting of two tranches of $50.0 million.

SEC original ↗Ardelyx, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

In June, the company drew $48.7 million in net proceeds under its term loan with SLR Investment Corp.

SEC original ↗Ardelyx, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

government-sponsored agency bonds 23,422 23,422 27,366 27,366 Corporate bonds 21,206 21,206 22,582 22,582 Yankee bonds 5,089 5,089 5,135 5,135 Total $ 274,744 $ 90,105 $ 184,639 $ $ 246,120 $ 49,430 $ 196,690 $ Fair Value of Debt The outstanding principal under our Loan Agreement is subject to a variable interest rate based on the one-month SOFR, a readily observable market data (Level 2 input).

SEC original ↗Ardelyx, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Therefore, we believe the carrying amount of the term loan facility approximated its fair value as of June 30, 2026 and December 31, 2025.

SEC original ↗Ardelyx, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Borrowing for more information.

SEC original ↗Ardelyx, Inc. — 10-Q Quarterly report10-QAug 6, 2026

This performance demonstrates that our strategy to provide access to XPHOZAH for all appropriate patients is working in this new market environment.

SEC original ↗Ardelyx, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Ardelyx is gaining momentum as we head into the second half of 2025, and we remain focused on commercial execution and bringing our medicines to patients who need more options.

SEC original ↗Ardelyx, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

IBSRELA delivered its highest demand quarter, including record highs for new and refill prescriptions and new and repeat writers, driven by a continued strategic focus on commercial execution and prescription pull-through.

SEC original ↗Ardelyx, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

NATURE OF OPERATIONS We are a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs.

SEC original ↗Ardelyx, Inc. — 10-Q Quarterly report10-QAug 6, 2026

In addition, we are building a pipeline which is currently focused on expanding the commercial footprint of tenapanor.

SEC original ↗Ardelyx, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Such forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control, that could cause actual outcomes or results to differ materially from those expressed or implied by the forward-looking statements.

SEC original ↗Ardelyx, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Such risks and uncertainties include, among others, uncertainties associated with the development of, regulatory process for, and commercialization of drugs in the U.

SEC original ↗Ardelyx, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ardelyx's business in general, please refer to Ardelyx s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 4, 2025, and its future current and periodic reports to be filed with the Securities and Exchange Commission.

SEC original ↗Ardelyx, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties.

SEC original ↗Ardelyx, Inc. — 10-Q Quarterly report10-QAug 6, 2026

These forward-looking statements include, but are not limited to, statements about: estimates of our expenses, future revenue, capital requirements, our needs for additional financing and our ability to obtain additional capital; and other risks and uncertainties, including those under the caption Risk Factors.

SEC original ↗Ardelyx, Inc. — 10-Q Quarterly report10-QAug 6, 2026

We have based these forward-looking statements largely on management s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and management s beliefs and assumptions, and these forward-looking statements are not guarantees of future performance or developments and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control, that could cause actual outcomes or results to differ materially from those expressed or implied by such forward-looking statements.

SEC original ↗Ardelyx, Inc. — 10-Q Quarterly report10-QAug 6, 2026